What is Orthopedia's earnings per share (EPS)?

Orthopedia (KIDS) reported diluted earnings per share of $-1.69 for fiscal year 2025. This represents a -3.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Orthopedia Financials

KIDS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Orthopedia (KIDS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 44/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Orthopedia has an operating margin of -16.6%, meaning the company retains $-17 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -17.1% the prior year.

Growth

Orthopedia's revenue surged 15.4% year-over-year to $236.3M, reflecting rapid business expansion. This strong growth earns a score of 59/100.

Leverage

Orthopedia carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 5.55, Orthopedia holds $5.55 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While Orthopedia generated -$4.9M in operating cash flow, capex of $11.1M consumed most of it, leaving -$16.0M in free cash flow. This results in a low score of 8/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Orthopedia generates a -11.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -10.7% the prior year.

Piotroski F-Score Neutral

4/9

Orthopedia passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.12x

For every $1 of reported earnings, Orthopedia generates $0.12 in operating cash flow (-$4.9M OCF vs -$39.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1453.3x

Orthopedia earns $-1453.3 in operating income for every $1 of interest expense (-$39.2M vs $27K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$236.3M

YoY+15.4%

5Y CAGR+27.2%

10Y CAGR+22.5%

Orthopedia generated $236.3M in revenue in fiscal year 2025. This represents an increase of 15.4% from the prior year.

EBITDA

-$18.1M

YoY-13.7%

Orthopedia's EBITDA was -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.7% from the prior year.

Net Income

-$39.6M

YoY-4.8%

Orthopedia reported -$39.6M in net income in fiscal year 2025. This represents a decrease of 4.8% from the prior year.

EPS (Diluted)

$-1.69

YoY-3.0%

Orthopedia earned $-1.69 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 3.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$16.0M

YoY+61.4%

Orthopedia generated -$16.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 61.4% from the prior year.

Cash & Debt

$19.6M

YoY-55.4%

5Y CAGR-7.4%

10Y CAGR+17.6%

Orthopedia held $19.6M in cash against $99.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

25M

YoY+3.6%

5Y CAGR+5.1%

Orthopedia had 25M shares outstanding in fiscal year 2025. This represents an increase of 3.6% from the prior year.

Margins & Returns

Gross Margin

73.0%

YoY+0.5pp

5Y CAGR-4.4pp

10Y CAGR+3.3pp

Orthopedia's gross margin was 73.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Operating Margin

-16.6%

YoY+0.5pp

5Y CAGR+21.0pp

10Y CAGR+4.7pp

Orthopedia's operating margin was -16.6% in fiscal year 2025, reflecting core business profitability. This is up 0.5 percentage points from the prior year.

Net Margin

-16.8%

YoY+1.7pp

5Y CAGR+29.6pp

10Y CAGR+8.7pp

Orthopedia's net profit margin was -16.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1.7 percentage points from the prior year.

Return on Equity

-11.4%

YoY-0.8pp

5Y CAGR+2.6pp

Orthopedia's ROE was -11.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$9.1M

YoY-17.5%

5Y CAGR+11.5%

10Y CAGR+17.7%

Orthopedia invested $9.1M in research and development in fiscal year 2025. This represents a decrease of 17.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$11.1M

YoY-22.1%

5Y CAGR+1.1%

10Y CAGR+17.5%

Orthopedia invested $11.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 22.1% from the prior year.

KIDS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$236.3M+15.4%	$204.7M+37.6%	$148.7M+21.6%	$122.3M+24.7%	$98.0M+37.9%	$71.1M
Cost of Revenue	$63.7M+13.5%	$56.1M+49.8%	$37.5M+18.5%	$31.6M+28.3%	$24.6M+53.6%	$16.0M
Gross Profit	$172.7M+16.2%	$148.6M+33.6%	$111.3M+22.7%	$90.7M+23.5%	$73.4M+33.4%	$55.0M
R&D Expenses	$9.1M-17.5%	$11.0M+1.3%	$10.9M+28.9%	$8.5M+52.5%	$5.5M+5.1%	$5.3M
SG&A Expenses	$119.8M+16.6%	$102.8M+40.2%	$73.3M+26.6%	$57.9M+25.7%	$46.1M+20.2%	$38.3M
Operating Income	-$39.2M-12.1%	-$35.0M-30.9%	-$26.8M-5.3%	-$25.4M-40.9%	-$18.0M+32.6%	-$26.8M
Interest Expense	$27K-22.9%	$35K-16.7%	$42K-92.0%	$525K+837.5%	$56K-98.4%	$3.4M
Income Tax	$460K+111.2%	-$4.1M-1115.1%	-$338K+93.2%	-$4.9M-338.6%	-$1.1M-56.0%	-$723K
Net Income	-$39.6M-4.8%	-$37.8M-80.3%	-$21.0M-1767.2%	$1.3M+107.7%	-$16.3M+50.6%	-$32.9M
EPS (Diluted)	$-1.69-3.0%	$-1.64-78.3%	$-0.92-1633.3%	$0.06+107.1%	$-0.84+53.8%	$-1.82

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$61.6M+0.6%	$61.3M+0.3%	$61.1M+16.5%	$52.4M-0.5%	$52.7M-3.5%	$54.6M+3.4%	$52.8M+18.2%	$44.7M
Cost of Revenue	$16.5M+3.3%	$16.0M-6.4%	$17.1M+20.6%	$14.1M-17.3%	$17.1M+17.8%	$14.5M+20.9%	$12.0M-4.1%	$12.5M
Gross Profit	$45.1M-0.4%	$45.3M+2.9%	$44.0M+15.0%	$38.3M+7.6%	$35.6M-11.2%	$40.1M-1.8%	$40.8M+26.8%	$32.2M
R&D Expenses	$2.3M-3.2%	$2.3M+8.1%	$2.2M-8.2%	$2.4M-19.4%	$2.9M+13.2%	$2.6M+1.3%	$2.5M-15.2%	$3.0M
SG&A Expenses	$30.0M+2.7%	$29.2M-4.2%	$30.4M+0.5%	$30.3M+23.9%	$24.4M-7.1%	$26.3M-3.8%	$27.3M+10.5%	$24.7M
Operating Income	-$8.2M+13.3%	-$9.4M+11.5%	-$10.7M+3.0%	-$11.0M+21.9%	-$14.1M-152.5%	-$5.6M+1.8%	-$5.7M+41.7%	-$9.7M
Interest Expense	-$4.5M-326.1%	$2.0M+56.1%	$1.3M+1.1%	$1.3M+176.0%	-$1.7M-276.7%	$945K+124.5%	$421K+24.2%	$339K
Income Tax	$340K+372.0%	-$125K-355.1%	$49K-75.0%	$196K+157.6%	-$340K+72.1%	-$1.2M-6666.7%	-$18K+99.3%	-$2.5M
Net Income	-$10.1M+14.2%	-$11.8M-65.5%	-$7.1M+33.3%	-$10.7M+33.7%	-$16.1M-102.9%	-$7.9M-31.3%	-$6.0M+22.8%	-$7.8M
EPS (Diluted)	N/A	$-0.50-66.7%	$-0.30+34.8%	$-0.46	N/A	$-0.34-30.8%	$-0.26+23.5%	$-0.34

KIDS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$508.6M+7.5%	$473.2M+7.9%	$438.7M+2.6%	$427.7M+40.6%	$304.3M-5.0%	$320.4M
Current Assets	$256.4M+8.1%	$237.2M+4.7%	$226.5M-0.1%	$226.7M+69.6%	$133.6M-15.6%	$158.4M
Cash & Equivalents	$19.6M-55.4%	$43.8M+41.1%	$31.1M+245.4%	$9.0M+17.7%	$7.6M-73.4%	$28.8M
Inventory	$133.8M+14.3%	$117.0M+10.5%	$105.9M+35.4%	$78.2M+35.8%	$57.6M+8.6%	$53.0M
Accounts Receivable	$53.8M+27.1%	$42.4M+22.4%	$34.6M+39.6%	$24.8M+38.2%	$17.9M+4.2%	$17.2M
Goodwill	$109.3M+16.4%	$93.8M+12.1%	$83.7M-3.6%	$86.8M+20.0%	$72.3M+2.6%	$70.5M
Total Liabilities	$162.0M+36.6%	$118.6M+92.2%	$61.7M+25.8%	$49.1M-37.8%	$78.9M-7.9%	$85.6M
Current Liabilities	$46.2M+36.0%	$34.0M-18.5%	$41.7M+35.0%	$30.9M+3.9%	$29.7M-15.2%	$35.0M
Long-Term Debt	$99.8M+36.8%	$73.0M+636.3%	$9.9M+1198.6%	$763K-15.9%	$907K-13.1%	$1.0M
Total Equity	$346.6M-2.2%	$354.6M-6.0%	$377.0M-0.4%	$378.6M+68.0%	$225.4M-4.0%	$234.8M
Retained Earnings	-$275.2M-16.8%	-$235.6M-19.1%	-$197.7M-11.9%	-$176.8M+0.7%	-$178.0M-10.1%	-$161.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$508.6M+3.1%	$493.5M-2.0%	$503.6M+7.1%	$470.3M-0.6%	$473.2M-3.3%	$489.3M+13.6%	$430.8M-1.5%	$437.2M
Current Assets	$256.4M+4.3%	$245.9M-4.6%	$257.7M+11.1%	$232.1M-2.2%	$237.2M-4.5%	$248.3M+28.1%	$193.8M-4.9%	$203.7M
Cash & Equivalents	$19.6M+16.2%	$16.8M-62.2%	$44.6M+33.2%	$33.4M-23.7%	$43.8M-14.2%	$51.0M+76.5%	$28.9M+33.9%	$21.6M
Inventory	$133.8M+3.9%	$128.8M+2.8%	$125.3M+4.6%	$119.8M+2.3%	$117.0M-3.2%	$120.9M+3.9%	$116.4M+3.3%	$112.7M
Accounts Receivable	$53.8M+5.0%	$51.3M-4.7%	$53.8M+22.3%	$44.0M+3.9%	$42.4M-1.1%	$42.8M+1.9%	$42.0M+15.9%	$36.3M
Goodwill	$109.3M+5.5%	$103.6M+4.6%	$99.0M+5.7%	$93.7M-0.2%	$93.8M+2.8%	$91.3M+0.8%	$90.5M-1.1%	$91.5M
Total Liabilities	$162.0M+12.4%	$144.2M-2.6%	$148.1M+20.3%	$123.1M+3.8%	$118.6M+0.2%	$118.4M+99.1%	$59.5M-10.7%	$66.6M
Current Liabilities	$46.2M+39.0%	$33.2M-14.1%	$38.7M+3.1%	$37.5M+10.4%	$34.0M-1.9%	$34.6M-12.5%	$39.6M-13.6%	$45.8M
Long-Term Debt	$99.8M+0.6%	$99.2M+2.2%	$97.0M+32.8%	$73.0M+0.1%	$73.0M+0.6%	$72.5M+641.3%	$9.8M-3.6%	$10.2M
Total Equity	$346.6M-0.8%	$349.3M-1.7%	$355.5M+2.4%	$347.1M-2.1%	$354.6M-4.4%	$370.9M-0.1%	$371.3M+0.2%	$370.6M
Retained Earnings	-$275.2M-3.8%	-$265.1M-4.6%	-$253.3M-2.9%	-$246.2M-4.5%	-$235.6M-7.3%	-$219.5M-3.7%	-$211.6M-2.9%	-$205.5M

KIDS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.9M+82.1%	-$27.0M0.0%	-$27.0M-24.3%	-$21.8M-66.6%	-$13.1M+29.5%	-$18.5M
Capital Expenditures	$11.1M-22.1%	$14.3M-15.5%	$16.9M+68.3%	$10.0M+23.8%	$8.1M-22.9%	$10.5M
Free Cash Flow	-$16.0M+61.4%	-$41.3M+5.9%	-$43.9M-38.1%	-$31.8M-50.2%	-$21.2M+27.1%	-$29.0M
Investing Cash Flow	-$43.6M-231.5%	-$13.2M-131.6%	$41.7M+136.8%	-$113.4M-1429.8%	-$7.4M+89.4%	-$69.7M
Financing Cash Flow	$24.0M-54.9%	$53.1M+627.8%	$7.3M-94.6%	$136.0M+2266133.3%	$6K-100.0%	$46.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$10.3M+1881.1%	-$581K+94.4%	-$10.5M-151.7%	-$4.2M-4.2%	-$4.0M+61.2%	-$10.3M-68.7%	-$6.1M+8.9%	-$6.7M
Capital Expenditures	$599K-78.9%	$2.8M-17.6%	$3.4M-18.5%	$4.2M+1713.4%	-$262K-119.0%	$1.4M-79.3%	$6.7M+3.5%	$6.5M
Free Cash Flow	$9.7M+385.1%	-$3.4M+75.4%	-$13.9M-65.9%	-$8.4M-97.3%	-$4.2M+63.6%	-$11.7M+8.7%	-$12.8M+2.8%	-$13.2M
Investing Cash Flow	-$7.3M+73.0%	-$26.8M-657.1%	-$3.5M+40.8%	-$6.0M-148.2%	-$2.4M+91.0%	-$26.8M-235.9%	$19.7M+635.4%	-$3.7M
Financing Cash Flow	-$417K-47.9%	-$282K-101.1%	$24.8M+19782.5%	-$126K+76.7%	-$541K-100.9%	$58.5M+1470.8%	-$4.3M-645.0%	-$573K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KIDS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	73.0%+0.5pp	72.6%-2.2pp	74.8%+0.7pp	74.1%-0.7pp	74.9%-2.6pp	77.4%
Operating Margin	-16.6%+0.5pp	-17.1%+0.9pp	-18.0%+2.8pp	-20.8%-2.4pp	-18.4%+19.3pp	-37.6%
Net Margin	-16.8%+1.7pp	-18.5%-4.4pp	-14.1%-15.1pp	1.0%+17.6pp	-16.6%+29.8pp	-46.4%
Return on Equity	-11.4%-0.8pp	-10.7%-5.1pp	-5.6%-5.9pp	0.3%+7.5pp	-7.2%+6.8pp	-14.0%
Return on Assets	-7.8%+0.2pp	-8.0%-3.2pp	-4.8%-5.1pp	0.3%+5.6pp	-5.3%+4.9pp	-10.3%
Current Ratio	5.55-1.4	6.98+1.5	5.44-1.9	7.34+2.8	4.50-0.0	4.52
Debt-to-Equity	0.29+0.1	0.21+0.2	0.03+0.0	0.000.0	0.000.0	0.00
FCF Margin	-6.8%+13.4pp	-20.2%+9.3pp	-29.5%-3.5pp	-26.0%-4.4pp	-21.6%+19.3pp	-40.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	73.2%-0.7pp	73.9%+1.8pp	72.1%-0.9pp	73.0%+5.5pp	67.5%-5.9pp	73.4%-3.9pp	77.3%+5.3pp	72.0%
Operating Margin	-13.3%+2.1pp	-15.4%+2.1pp	-17.4%+3.5pp	-20.9%+5.7pp	-26.7%-16.5pp	-10.2%+0.5pp	-10.7%+11.0pp	-21.8%
Net Margin	-16.4%+2.8pp	-19.2%-7.6pp	-11.7%+8.7pp	-20.3%+10.2pp	-30.5%-16.0pp	-14.5%-3.1pp	-11.4%+6.0pp	-17.5%
Return on Equity	-2.9%+0.5pp	-3.4%-1.4pp	-2.0%+1.1pp	-3.1%+1.5pp	-4.5%-2.4pp	-2.1%-0.5pp	-1.6%+0.5pp	-2.1%
Return on Assets	-2.0%+0.4pp	-2.4%-1.0pp	-1.4%+0.9pp	-2.3%+1.1pp	-3.4%-1.8pp	-1.6%-0.2pp	-1.4%+0.4pp	-1.8%
Current Ratio	5.55-1.8	7.40+0.7	6.66+0.5	6.19-0.8	6.98-0.2	7.17+2.3	4.90+0.5	4.45
Debt-to-Equity	0.290.0	0.28+0.0	0.27+0.1	0.210.0	0.21+0.0	0.20+0.2	0.030.0	0.03
FCF Margin	15.8%+21.4pp	-5.6%+17.2pp	-22.8%-6.8pp	-16.0%-7.9pp	-8.1%+13.3pp	-21.4%+2.8pp	-24.2%+5.2pp	-29.4%

Similar Companies

ZIMVIE INC ZIMV

$535.7M

Treace Medical Concepts, Inc. TMCI

$86.6M

Cytek Biosciences, Inc. CTKB

$561.8M

STANDARD BIOTOOLS INC LAB

$358.6M

Bioventus Inc. BVS

$615.1M

Frequently Asked Questions

What is Orthopedia's annual revenue?

Orthopedia (KIDS) reported $236.3M in total revenue for fiscal year 2025. This represents a 15.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Orthopedia's revenue growing?

Orthopedia (KIDS) revenue grew by 15.4% year-over-year, from $204.7M to $236.3M in fiscal year 2025.

Is Orthopedia profitable?

No, Orthopedia (KIDS) reported a net income of -$39.6M in fiscal year 2025, with a net profit margin of -16.8%.

What is Orthopedia's EBITDA?

Orthopedia (KIDS) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Orthopedia have?

As of fiscal year 2025, Orthopedia (KIDS) had $19.6M in cash and equivalents against $99.8M in long-term debt.

What is Orthopedia's gross margin?

Orthopedia (KIDS) had a gross margin of 73.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Orthopedia's operating margin?

Orthopedia (KIDS) had an operating margin of -16.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Orthopedia's net profit margin?

Orthopedia (KIDS) had a net profit margin of -16.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Orthopedia's return on equity (ROE)?

Orthopedia (KIDS) has a return on equity of -11.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Orthopedia's free cash flow?

Orthopedia (KIDS) generated -$16.0M in free cash flow during fiscal year 2025. This represents a 61.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Orthopedia's operating cash flow?

Orthopedia (KIDS) generated -$4.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Orthopedia's total assets?

Orthopedia (KIDS) had $508.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Orthopedia's capital expenditures?

Orthopedia (KIDS) invested $11.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Orthopedia spend on research and development?

Orthopedia (KIDS) invested $9.1M in research and development during fiscal year 2025.

How many shares does Orthopedia have outstanding?

Orthopedia (KIDS) had 25M shares outstanding as of fiscal year 2025.

What is Orthopedia's current ratio?

Orthopedia (KIDS) had a current ratio of 5.55 as of fiscal year 2025, which is generally considered healthy.

What is Orthopedia's debt-to-equity ratio?

Orthopedia (KIDS) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Orthopedia's return on assets (ROA)?

Orthopedia (KIDS) had a return on assets of -7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Orthopedia's cash runway?

Based on fiscal year 2025 data, Orthopedia (KIDS) had $19.6M in cash against an annual operating cash burn of $4.9M. This gives an estimated cash runway of approximately 48 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Orthopedia's Piotroski F-Score?

Orthopedia (KIDS) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Orthopedia's earnings high quality?

Orthopedia (KIDS) has an earnings quality ratio of 0.12x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Orthopedia cover its interest payments?

Orthopedia (KIDS) has an interest coverage ratio of -1453.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Orthopedia?

Orthopedia (KIDS) scores 44 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.